-+ 0.00%
-+ 0.00%
-+ 0.00%

Mesoblast Reports Substantial Revenue Growth to US$120M

Barchart·08/26/2026 19:32:00
Listen to the news

RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment

Financial Results and Operational Update for Full Year Ended June 30, 2026

Read more at globenewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.